WO2001051517A9 - Candida hemolysin - like proteins and their uses - Google Patents
Candida hemolysin - like proteins and their usesInfo
- Publication number
- WO2001051517A9 WO2001051517A9 PCT/US2001/000815 US0100815W WO0151517A9 WO 2001051517 A9 WO2001051517 A9 WO 2001051517A9 US 0100815 W US0100815 W US 0100815W WO 0151517 A9 WO0151517 A9 WO 0151517A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- seq
- vaccine
- polynucleotide
- nos
- Prior art date
Links
- 241000222120 Candida <Saccharomycetales> Species 0.000 title claims abstract description 46
- 101000664359 Synechocystis sp. (strain PCC 6803 / Kazusa) S-layer protein Proteins 0.000 title abstract description 86
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 49
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 49
- 229920001184 polypeptide Polymers 0.000 claims abstract description 47
- 229960005486 vaccine Drugs 0.000 claims abstract description 33
- 230000000890 antigenic effect Effects 0.000 claims abstract description 19
- 230000028993 immune response Effects 0.000 claims abstract description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 100
- 102000004169 proteins and genes Human genes 0.000 claims description 66
- 108091033319 polynucleotide Proteins 0.000 claims description 53
- 102000040430 polynucleotide Human genes 0.000 claims description 53
- 239000002157 polynucleotide Substances 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 38
- 150000001413 amino acids Chemical class 0.000 claims description 26
- 239000012634 fragment Substances 0.000 claims description 21
- 125000000539 amino acid group Chemical group 0.000 claims description 16
- 239000002671 adjuvant Substances 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 6
- 230000027455 binding Effects 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 238000013518 transcription Methods 0.000 claims description 4
- 230000035897 transcription Effects 0.000 claims description 4
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims description 3
- 230000024932 T cell mediated immunity Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 244000197813 Camelina sativa Species 0.000 abstract description 49
- 230000002949 hemolytic effect Effects 0.000 abstract description 39
- 108010006464 Hemolysin Proteins Proteins 0.000 abstract description 27
- 239000003228 hemolysin Substances 0.000 abstract description 21
- 230000014509 gene expression Effects 0.000 abstract description 10
- 244000052769 pathogen Species 0.000 abstract description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract description 6
- 230000001105 regulatory effect Effects 0.000 abstract description 5
- 230000001681 protective effect Effects 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 48
- 241000222122 Candida albicans Species 0.000 description 41
- 210000004027 cell Anatomy 0.000 description 41
- 108020004414 DNA Proteins 0.000 description 31
- 235000001014 amino acid Nutrition 0.000 description 16
- 229940024606 amino acid Drugs 0.000 description 15
- 238000003556 assay Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 13
- 239000000427 antigen Substances 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 206010007134 Candida infections Diseases 0.000 description 10
- 201000003984 candidiasis Diseases 0.000 description 10
- 230000001717 pathogenic effect Effects 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 108010044091 Globulins Proteins 0.000 description 8
- 102000006395 Globulins Human genes 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 206010018910 Haemolysis Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 230000008588 hemolysis Effects 0.000 description 7
- 230000000521 hyperimmunizing effect Effects 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 239000002689 soil Substances 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 6
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 230000001747 exhibiting effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000001018 virulence Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
- 229960000310 isoleucine Drugs 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101150063922 HLP gene Proteins 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 208000031888 Mycoses Diseases 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 3
- 229960003942 amphotericin b Drugs 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000006161 blood agar Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241001416152 Bos frontalis Species 0.000 description 2
- 241000244203 Caenorhabditis elegans Species 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229920000057 Mannan Polymers 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000009137 competitive binding Effects 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000007421 fluorometric assay Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003219 hemolytic agent Substances 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000005065 mining Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000025687 phenotypic switching Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000000304 virulence factor Substances 0.000 description 2
- 230000007923 virulence factor Effects 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- YSCNMFDFYJUPEF-OWOJBTEDSA-N 4,4'-diisothiocyano-trans-stilbene-2,2'-disulfonic acid Chemical compound OS(=O)(=O)C1=CC(N=C=S)=CC=C1\C=C\C1=CC=C(N=C=S)C=C1S(O)(=O)=O YSCNMFDFYJUPEF-OWOJBTEDSA-N 0.000 description 1
- 101150111160 ALA1 gene Proteins 0.000 description 1
- 101150118692 ALS5 gene Proteins 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000004580 Aspartic Acid Proteases Human genes 0.000 description 1
- 108010017640 Aspartic Acid Proteases Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108010023063 Bacto-peptone Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000237970 Conus <genus> Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102100038285 Endogenous retroviral envelope protein HEMO Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 101710082714 Exotoxin A Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229940121672 Glycosylation inhibitor Drugs 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001033183 Homo sapiens Endogenous retroviral envelope protein HEMO Proteins 0.000 description 1
- 101000614399 Homo sapiens Serine/threonine-protein phosphatase 2A regulatory subunit B'' subunit beta Proteins 0.000 description 1
- 101000664887 Homo sapiens Superoxide dismutase [Cu-Zn] Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102100040471 Serine/threonine-protein phosphatase 2A regulatory subunit B'' subunit beta Human genes 0.000 description 1
- 101100177443 Spinacia oleracea HEMB gene Proteins 0.000 description 1
- 206010042938 Systemic candida Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010064899 Vulvovaginal mycotic infection Diseases 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000007801 affinity label Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000037815 bloodstream infection Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000013368 commensalism Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000003391 densitometric scan Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 238000012203 high throughput assay Methods 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 244000309462 non-albicans Candida Species 0.000 description 1
- -1 nucleic acid compound Chemical class 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 239000007222 ypd medium Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
- C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
- C07K14/40—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Candida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- Candida albicans and C. glabrata present a growing risk to public health
- the yeast Candida species can exist both as a non-virulent colonizer (commensal) and as a pathogen.
- Candidiasis has become increasingly widespread during the last two decades, with hospitalized and immunocompromised patients at greatest risk, and has become the sixth most common form of pathogenic infection.
- Systemic Candida infections may be lethal, with a mortality rate of 50% in adults and up to 65% in infants.
- the risk of death from systemic infection most strongly correlates with the time between the first detected infection and the onset of antifungal treatment. Pacheco-Rios et al. (1997).
- Candida albicans accounts for 50-70% of candidiasis cases, although a progressively larger proportion of cases are caused by non-albicans species.
- C. glabrata (formerly Torulopsis glabrata) has emerged as one of the three most common Candida species colonizing humans (Fidel et al. (1999); Hazen et al. (1995)) and it now represents the second most common Candida species causing blood stream infections (Pfaller et al. (1996)) and one of the most prevalent species responsible for yeast vaginitis (Sobel et al. (1996); Spinillo et al. (1995)). A dramatic increase in the carriage of C.
- C. albicans exhibits a bud-hypha phenotype transition, which occurs en masse in response to various stimuli, and provides C. albicans with the capacity to penetrate tissue and to disseminate. Odds (1997). C. albicans also undergoes spontaneous, reversible, high frequency switching of phenotypes, which usually does not occur en masse. In C. albicans strain WO-1, switching occurs reversibly between a phenotype characterized by white colonies and a phenotype characterized by opaque colonies. Soil (1992). In C.
- the present invention addresses these needs by providing, from Candida yeast such as C. glabrata, a hemolysin-like protein (HLP) and its encoding polynucleotide.
- Candida yeast such as C. glabrata
- HLP hemolysin-like protein
- the inventors' discovery of an HLP in C. glabrata led to their identifying a similar C. albicans HLP and encoding gene.
- the inventors have found that C. glabrata, like C. albicans, undergoes phenotype switching, which regulates the expression of the C. glabrata HLP.
- HLP expression coincides with hemolytic activity, and it is expected that a phenotype expressing an HLP will have virulent properties conferred by the hemolytic activity of that HLP.
- the HLP of the invention is expected to exhibit hemolytic activity also because of structural similarity to partial ( ⁇ -type) or complete ( ⁇ -type) hemolysins identified in a number of other pathogens
- HLP polypeptides of the invention are antigenic and are useful as vaccine components to raise a protective immune response against Candida. Further, antibodies directed against a Candida HLP, or an antigenic fragment thereof, are useful in indicating the presence of a virulent phenotype. The antibodies also can be used to protect against or ameliorate candidiasis associated with a virulent Candida phenotype. In one embodiment, antibodies raised by an HLP protein, or an antigenic fragment thereof, are capable of inhibiting hemolytic activity of an HLP.
- the invention provides a vaccine, comprising: (i) an antigemc polypeptide comprising 10 contiguous amino acid residues of either of the proteins shown in SEQ ID NOS:2 or 4; or
- a polynucleotide encoding an antigenic polypeptide comprising 10 contiguous amino acid residues of either of the proteins shown in SEQ ID NOS: 2 or 4, wherein the polynucleotide is operably linked to a promoter capable of driving transcription in a host cell; and (iii) a pharmaceutically acceptable adjuvant or carrier vehicle.
- the polypeptide component of this vaccine alternately may comprise 12 contiguous amino acids of either of the proteins shown in SEQ ID NOS: 2 or 4. Alternately, it may comprise 30 or 40 contiguous amino acids of either of the proteins shown in SEQ ID NOS: 2 or 4.
- the carrier vehicle is a protein that is covalently conjugated to the polypeptide.
- the vaccine comprises either of the proteins shown in SEQ ID NOS:2 or 4.
- the vaccine alternately may comprise a polynucleotide encoding a polypeptide comprising 10, 12, 30, or 40 contiguous amino acids of either of the proteins shown in SEQ ID NOS:2 or 4.
- the polynucleotide encodes either of the proteins shown in SEQ ID NOS:2 or 4.
- a method of diagnosing a virulent phenotype of Candida comprises exposing a body fluid from an individual suspected of having a virulent phenotype of Candida with a detectably labeled antibody that is capable of binding an HLP of Candida.
- a method of treatment of an individual infected with a virulent phenotype of Candida comprises adrninistration of a pharmaceutical composition that comprises an antibody that is capable of binding an HLP of Candida.
- a method of inducing an immune response comprises administering to an individual a pharmaceutical composition that comprises either: (i) an antigenic polypeptide comprising 10 contiguous amino acid residues of either of the proteins shown in SEQ ID NOS: 2 or 4; or (ii) a polynucleotide encoding an antigenic polypeptide comprising 10 contiguous amino acid residues of either of the proteins shown in SEQ ID NOS: 2 or 4, wherein the polynucleotide is operably linked to a promoter capable of driving transcription in a host cell; and (iii) a pharmaceutically acceptable adjuvant or carrier vehicle.
- Another embodiment of the invention is an isolated polynucleotide that exhibits greater than about 80% sequence identity to polynucleotide sequence SEQ ID NO:l, or a polynucleotide having the sequence shown in SEQ ID NO:l, or a polynucleotide encoding a polypeptide having the sequence shown in SEQ ID NO:2.
- Polypeptides encoded by the polynucleotides are encompassed by the invention, including a polypeptide having the sequence shown in SEQ ID NO:2.
- Antigenic fragments preferably comprises at least 30 contiguous amino acids of the protein shown in SEQ ID NO:2.
- FIGURE 1 A cloned C. glabrata genomic DNA fragment that is 1532 nucleotides in length (SEQ ID NO : 1).
- FIGURE 2 The polynucleotide sequence of a C. albicans HLP-encoding DNA, including a promoter region, cloned from C. albicans strain WO-1 (SEQ ID NO: 3).
- FIGURE 3 Comparison of the deduced amino acid sequence of a C. glabrata HLP ("CgHLP”; SEQ ID NO:2) and C. albicans HLP ("CaHLP”; SEQ ID NO:4).
- CgHLP C. glabrata HLP
- CaHLP C. albicans HLP
- FIGURE 4 Comparison of five regions with high similarity in both position and arrangements of amino acids among a C. glabrata and C. albicans HLP and hemolysins from seventeen bacteria and Caenorhabditis elegans.
- Candida hemolysin-like proteins and presently disclose HLPs from C. albicans and C. glabrata.
- the inventors have further discovered a novel phenotype switching in C. glabrata.
- C. glabrata reversibly switches among white (Wh), light brown (LB) and dark brown (DB) colony phenotypes.
- Switching in C. glabrata, as in C. albicans is believed to represent a general strategy for the combinatorial expression of genes encoding proteins involved in virulence.
- the C. glabrata HLP is expressed preferentially in different phenotypes, and, by analogy with C.
- the phenotype expressing the HLP at high levels is expected to express other virulence factors at high levels.
- Hemolytic activity will play a particularly important role in pathogenesis, especially in systemic infection by Candida, where circulating red blood cells are exposed directly to the pathogens. It has been postulated that Candida acquires iron that is liberated from lysed red blood cells of the infected host. Manns et al. (1994). Further, in various ways beyond the outright loss of red blood cells, hemolysis impairs the health of the host and contributes to mortality from systemic infection. Reviewed in Maslow et al. (1999); Traub et al. (1996); May et al. (1996); hacker et al. (1983). Accordingly, inhibition of hemolytic activity will be valuable in the treatment of candidiasis.
- antibodies against an HLP inhibit hemolytic activity.
- HLP hemolytic lipoprotein
- association of HLP with hemolytic activity is, itself, sufficient to identify a phenotype that expresses high levels of an HLP as a virulent phenotype.
- any Candida phenotype that expresses an HLP is defined as a "virulent phenotype,” for the purposes of this invention.
- FIGURE 1 shows a cloned C. glabrata genomic DNA fragment that is 1532 nucleotides in length and encodes an HLP with three putative trans-membrane domains.
- the discovery of a hemolysin-like gene in C. glabrata prompted the inventors to investigate the possible presence of a similar gene in C. albicans.
- the polynucleotide sequence of an HLP gene in C. albicans is shown in
- FIGURE 2 (SEQ ID NO:2).
- FIGURE 3 SEQ ID NOS:2 and 4).
- FIGURE 4 The mean percent identity of region 1 of the deduced
- C. glabrata protein sequence and hemolysins from 16 unrelated organisms was 72+ 12%; percent identity ranged between 42 and 92% , where "percent identity” refers to the similarity between sequences based on the BLASTX-BEAUTY sequence alignment algorithm, using the indicated C. glabrata sequence as a reference sequence.
- the mean percent identities of regions 2, 3, 4 and 5 were 59 + 16% , 50+ 10%, 60+ 14% and 73 + 11 %, respectively.
- the relative positions of all five regions in the deduced partial C. glabrata protein were similar to those in the majority of hemolysins of other organisms.
- the deduced primary C. glabrata HLP sequence of 508 amino acids exhibits 75% identity to the corresponding region of the S. cerevisiae YOL060c gene product.
- a C. albicans hemolytic factor has recently been identified by Wanatabe et al. (1999). This factor has been partially characterized and is primarily a polysaccharide, consisting of 95% carbohydrate by weight. It co-migrates with Blue Dextran on a Sephacryl S-100 column, indicating that if has an apparent molecular weight of at least 200 kDa, and it is a mannan. It is not believed that the mannan described by Wanatabe et al. is structurally related to the C. albicans HLP shown in SEQ ID NO: 4.
- hemolysin-like protein denotes a polypeptide having the amino acid sequence shown in SEQ ID NO:2, which is a C. glabrata HLP, or having the amino acid sequence shown in SEQ ID NO:4, which is a C. albicans HLP.
- Naturally occurring and synthetically produced variants of these two proteins also are embraced by “hemolysin-like protein.
- "Variants” encompass, for example, naturally occurring HLPs, including HLPs from other Candida species and allelic variations of these proteins.
- variants in this context also are fragments of the aforementioned proteins that are antigenic when administered with an adjuvant or carrier vehicle. Preferably, fragments are contiguous stretches of amino acids of the proteins of SEQ ID NOS:2 and 4 that are 5, 10, 12, 15, 20, 30, or 40 amino acids in length.
- variants further include polypeptides that have a modified amino acid sequence from the aforementioned polypeptides.
- sequence modifications include amino acid substitutions, insertions, and deletions. Amino acid insertions and deletions may be made in the interior of the protein sequence, as well as at the amino and carboxyl termini. Guidance in determining which and how many such sequence modifications may be made without abolishing biological or antigenic activity may be found using computer programs well known in the art, for example, DNASTAR software (DNASTAR Inc., 1801 Univerity Ave. , Madison, WI 53705) .
- substitutions preferably are conservative, that is, one amino acid is replaced with one of similar shape and charge.
- Conservative substitutions are well known in the art and include, for example, the changes of: alanine to serine; arginine to lysine; asparigine to glutamine or histidine; aspartate to glutamate; cysteine to serine; glutamine to asparigine; glutamate to aspartate; glycine to proline; histidine to asparigine or glutamine; isoleucine to leucine or valine; leucine to valine or isoleucine; lysine to arginine, glutamine, or glutamate; methionine to leucine or isoleucine; phenylalanine to tyrosine, leucine or methionine; serine to threonine; threonine to serine; tryptophan to tyrosine; tyrosine to tryptophan or phenylalan
- variants preferably will have an 80% identity to the full length proteins shown in SEQ ID NOS: 2 and 4.
- percent identity is determined by the BLASTX-BEAUTY sequence algorithm, where the test sequence is aligned and compared to either sequences set forth in SEQ ID NOS: 2 and 4. More preferably, variants will have at least about 85% identity to these sequences. Even more preferably, the percent identity will be at least about 90 % , and most preferably, the percent identity will be at least about 95 % , or even 98% .
- variants of fragments of the proteins of SEQ ID NOS:2 and 4 will be useful for the invention, for instance, as antigenic fragments.
- Such variants will have at least about 85% identity to fragments of the proteins of SEQ ID NOS:2 and 4. Even more preferably, the percent identity will be at least about 90%, and most preferably, the percent identity will be at least about 95%, or even 98%. Preferably, antigenic fragments will be at least 30 amino acids in length.
- Additional polypeptide sequences or other moieties, such as covalently attached, detectable tags, may be added to the proteins of the invention. Additional polypeptide sequences may fused to either the amino or carboxyl termini of the polypeptides of the invention, and they may be useful, for example, in assisting the expression, purification, and/or detection proteins of the invention. For example, these various sequences include those well known in the art that are useful in purification of recombinantly expressed proteins.
- a preferred fusion protein comprises a "His tag" sequence, which facilitates purification of the recombinantly expressed protein.
- a preferred system is the TALONTM nondenaturing protein purification kit for purifying 6xHis-tagged proteins under native conditions (CLONTECH, Palo Alto, CA).
- isolated polypeptides are not in a naturally occurring form and/or have been purified to remove at least some portion of cellular or non-cellular molecules with which the proteins are naturally associated.
- the present HLPs may be isolated by the methodology described by Herbelin et al. (1995) for the purification of hemolysins, for example.
- an HLP is expected to exhibit hemolytic activity, as set forth above.
- an HLP variant exhibits hemolytic activity. It is expected that a hemolytically active HLP variant will include some or all of the structural elements that are conserved among known hemloysins, indicated in FIGURE 4.
- the HLPs of the invention bear closest resemblance to hemolysins that exhibit partial ( ⁇ -type) or complete ( ⁇ -type) hemolysis. Fairweather et al. (1983); Helms et al. (1977); Li et al. (1999); Leao et al. (1995).
- Hemolytic activity can be tested by any of several routine assays well known in the art. These assays include inspection of cells exposed to hemolysins by light microscopy, release of detectable cytoplasmic proteins, such as hemoglobin or enzymes, Trypan blue exclusion, or Evans blue-albumin flux. Gibson et al. (1999); Thelestam et al. (1994). Additional assays include a hemolytic plate assay or cell free broth assay, as described in Parveen (1992). Alternately, a fluorometric assay, using erythrocyte ghosts, may be used, as described in Serra et al. (1992).
- These assays can be used to test the ability of compounds to inhibit the hemolytic activity of an HLP or an HLP variant.
- High throughput assays designed around one of the assays described above, for example, can simultaneously test a plurality of candidate compounds.
- Antibodies will be screened using a hemolytic assay to identify those antibodies with inhibitory activity, which will allow the identification of potentially therapeutically useful antibodies.
- This screening method can also be applied to other candidate molecules, such as drugs, to identify those with inhibitory activity.
- drugs are expected to be useful as components of a pharmaceutical composition for treatment of candidiasis.
- HLP polynucleotides of the invention A polynucleotide of the mvention encodes any polypeptide of the invention, and includes all the possible combinations of codons that encode particular amino acids. Polynucleotides of the invention, in addition to encoding polypeptides, may be useful as oligonucleotide probes for the identification of other HLP polynucleotides, as set forth in the Examples below.
- a polynucleotide comprises at least 5 nucleotides of a nucleic acid (RNA, DNA, a combination thereof, or analogues thereof), provided by any means, such as synthetic purification.
- Polynucleotides having at least about 10 nucleotides are preferred, and polynucleotides having at least about 20 nucleotides are more preferred.
- the nucleotide sequence of an HLP gene fragment shown in FIGURE 1 (SEQ ID NO:l) has been deposited in the National Center for Biological Information under accession number AF196836.
- the invention also provides vectors and host cells that comprise the polynucleotides of the invention.
- Host cells include any eukaryotic, prokaryotic, or other cell that is suitable for propagating and/or expressing an isolated nucleic acid that is introduced into the host cell by any suitable means known in the art.
- the cell can be part of a tissue or organism, isolated in culture or in any other suitable form.
- Vectors include any nucleic acid compound used for introducing exogenous nucleic acid into host cells.
- a vector comprises a nucleotide sequence which may encode one or more polypeptide molecules.
- Plasmids, cosmids, viruses, and bacteriophages, in a natural state or which have undergone recombinant engineering are non-limiting examples of commonly used vectors to provide recombinant vectors comprising at least one desired isolated nucleic acid molecule. Reviewed in Sambrook et al. (1989) and Ausubel et al. (1989). Because of the similarity of the HLP proteins to partial ( ⁇ -type) or complete ( ⁇ -type) hemolysis, it is expected that they will be functional hemolysins in secreted form. Accordingly, preferred expression vectors comprise any of the well-characterized secretion signals.
- a host cell of the invention strain may be chosen for its ability to post- translationally modify the expressed recombinant protein.
- modifications of the polypeptide include, for example, glycosylation and acylation.
- Post-translational processing which cleaves a nascent form of the protein may also be important for correct secretion, folding and/or function.
- Different host cells may be chosen to ensure the correct modification and processing of the recombinantly expressed protein.
- Isolated polynucleotides are removed from their native or naturally occurring environment. For example, recombinant polynucleotides within vectors are considered isolated for the purposes of the present invention. Isolated polynucleotides include in vivo or in vitro RNA transcripts of the polynucleotides of the invention. Isolated polynucleotides further include synthetically produced molecules, where the nucleic acid in other than a naturally occurring form. Isolated polynucleotides include genomic DNA that has been removed from the chromosome in which it occurs naturally.
- Candida HLPs and antigenic fragments thereof will be useful as components of a vaccine.
- a vaccine comprises HLP from C. albicans or C. glabrata, or antigenic fragments thereof.
- Particularly useful vaccines will raise antibodies that block or inhibit the hemolytic activity of the protein. Such antibodies can be screened in vitro, using the various hemolysis assays described above.
- Polyclonal antiserum containing antibodies to heterogenous epitopes of a single protein, can be prepared by immunizing suitable animals with the expressed protein described above, which can be unmodified or modified, as known in the art, to enhance immunogenicity. Immunization methods include subcutaneous or intraperitoneal injection of the polypeptide.
- the protein immunogen may be modified or administered in an adjuvant in order to increase the protein's antigenicity.
- adjuvants include Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and Corynebacterium parvum.
- HLP antigens alternately may be conjugated to a carrier vehicle, or "immunocarrier,” to improve the interaction between T and B cells for the induction of an immune response against the antigen. This is particularly preferable for the production of vaccines in immunocompromised individuals, who also will be those predisposed to candidiasis.
- Preferred carrier vehicles are proteins that are covalently conjugated to a HLP polypeptide of the invention. Proteins useful as carrier vehicles are well known in the art and include tetanus toxoid, diphtheria toxoid, P. aeruginosa exotoxin A, and variants thereof, as described, for example, in Fattom et al. (1993).
- Effective polyclonal antibody production is affected by many factors related both to the antigen and to the host species. For example, small molecules tend to be less immunogenic than other and may require the use of carriers and/or adjuvant. In addition, host animal response may vary with site of inoculation. Both inadequate or excessive doses of antigen may result in low titer antisera. In general, however, small doses (high ng to low ⁇ g levels) of antigen administered at multiple intradermal sites appears to be most reliable. Host animals may include but are not limited to rabbits, mice, and rats, to name but a few. An effective immunization protocol for rabbits can be found in Vaitukaitis et al. (1971). Affinity of the antisera for the antigen may be determined by preparing competitive binding curves, as described, for example, by Fisher(1980). ii) Monoclonal Antibodies
- Monoclonal antibodies may be obtained by any technique that provides for the production of antibody molecules by continuous cell lines in culture or in vivo. MAbs may be produced by making hybridomas, which are immortalized cells capable of secreting a specific monoclonal antibody. Monoclonal antibodies to any of the proteins, peptides and epitopes thereof described herein can be prepared from murine hybridomas according to the classical method of Kohler et al. (1975) and US 4,376,110, or modifications of the methods thereof. Such modifications include the human B-cell hybridoma technique (Kosbor et al. (1983)) and the EBV-hybridoma technique (Cole et al. (1985)). iii) Antibody Derivatives and Fragments
- Fragments or derivatives of antibodies include any portion of the antibody which is capable of binding the target antigen, or a specific portion thereof.
- Antibody fragments specifically include F(ab') 2 , Fab, Fab' and Fv fragments. They may be made by conventional recombinant DNA techniques or, using the classical method, by proteolytic digestion with papain or pepsin. See Current Protocols in Immunology, chapter 2, Coligan et al. , eds., John Wiley & Sons (1991-92). Other antibody derivatives include single chain antibodies. US 4,946,778; Bird (1988); Huston et al. (1988). Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain FV (SCFv) .
- SCFv single chain FV
- chimeric antibodies also include "chimeric antibodies. " Morrison et al. (1984); Neuberger et al (1984); Takeda et al. (1985). These chimeras are made by splicing the DNA encoding a mouse antibody molecule of appropriate specificity with, for instance, DNA encoding a human antibody molecule of appropriate specificity.
- a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine rnAb and a human immunoglobulin constant region. These are also known sometimes as "humanized” antibodies and they offer the added advantage of at least partial shielding from the human immune system. They are, therefore, particularly useful in therapeutic in vivo applications.
- the present invention further provides the above-described antibodies in detectably labeled form.
- Antibodies can be detectably labeled through the use of radioisotopes, affinity labels (such as biotin, avidin, etc.), enzymatic labels (such as horseradish peroxidase, alkaline phosphatase, etc.) fluorescent labels (such as FITC or rhodamine, etc.), paramagnetic atoms, etc. Labeling procedures are well known in the art, for example see Sternberger et al. (1970); Bayer et al. (1979); Engval et al. (1972).
- the labeled antibodies of the present invention can be used for in vitro, in vivo, and in situ diagnostic assays.
- the foregoing antibodies also may be immobilized on a solid support.
- solid supports include plastics such as polycarbonate, complex carbohydrates such as agarose and sepharose, acrylic resins and such as polyacrylamide and latex beads. Techniques for coupling antibodies to such solid supports are well known in the art. Weir et al. (1986).
- the immobilized antibodies of the present invention can be used for in vitro, in vivo, and in situ assays as well as for immunoaffinity purification of the proteins of the present invention.
- DNA vaccines DNA-based immunization refers to the induction of an immune response to an antigen expressed in vivo from a gene introduced into the animal. This method offers two major advantages over classical vaccination in which some form of the antigen itself is administered.
- Genes have been introduced directly into animals by using live viral vectors containing particular sequences from an adeno virus, an adeno-associated virus, or a retrovirus genome.
- the viral sequences allow the appropriate processing and packaging of a gene into a virion, which can be introduced to animals through invasive or non-invasive infection. Naked DNA transfects relatively efficiently if injected into skeletal muscle. Wolff et al. (1990).
- plasmid DNA may be coated onto the surface of small gold particles and introduced into the skin by a helium-driven particle accelerator, or "gene-gun.”
- DNA has also been introduced into animal cells by liposome-mediated gene transfer. DNA-liposome complexes, usually containing a mixture of cationic and neutral lipids, are injected intravenously or into various tissues or instilled into the respiratory passages. Nabel et al. (1992).
- a variety of protocols useful for detecting and measuring the presence of HLPs of the invention in body fluids or tissue and cell extracts, using either polyclonal or monoclonal antibodies specific for the protein, are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS).
- ELISA enzyme-linked immunosorbent assay
- RIA radioimmunoassay
- FACS fluorescent activated cell sorting
- a two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes may be employed.
- Well known competitive binding techniques may also be employed. See, e.g. , Hampton et al. (1990); Coligan et al. (1997 and periodic supplements); and Maddox et al. (1983).
- test kits which comprise HLP proteins of the invention or HLP-specific antibodies.
- test kits can be in solid phase or liquid phase formats, and they can be based on immunohistochemical assays, ELISAs, particle assays, radiometric or fluorometric assays, using, for example, avidin/biotin technology.
- a vaccine of the present invention can be administered to a subject who then acts as a source for globulin, produced in response to challenge from the specific vaccine ("hyperimmune globulin"), that contains antibodies directed against an HLP of the invention.
- hyperimmune globulin produced in response to challenge from the specific vaccine
- US 5,770,208 A subject thus treated would donate plasma from which hyperimmune globulin would then be obtained, via conventional plasma-fractionation methodology, and administered to another subject in order to impart resistance against or to treat Candida infection.
- Hyperimmune globulins according to the invention are particularly useful for immune-compromised individuals, for individuals undergoing invasive procedures or where time does not permit the individual to produce his own antibodies in response to vaccination.
- a method of preparing an immunotherapeutic agent against Candida infection comprises steps of immunizing subjects with a composition according to the invention, collecting plasma from the immunized subjects, and harvesting a hyperimmune globulin that contains antibodies directed against Candida from the collected plasma.
- the hyperimmune globulin contains antibodies directed against the HLPs of the invention.
- An immunotherapy method comprises a step of administering this hyperimmune globulin to a subject.
- Hyperimmune globulins would preferably be administered in the presence of known compounds that are useful for treating Candida.
- Amphotericin B is one such compound. Fluconazole has been shown to be an effective and safe alternative in non-neutropenic patients. 5-Fluorocytosine has been used in combination with amphotericin B in the treatment of deep-seated infections. Liposomal formulations of amphotericin B and other antifungal drugs may be used. Verduyn Lunel et al. (1999 ).
- C. glabrata HLP is regulated by switching, with the order of transcript levels of the various phenotypes DB > LB > Wh.
- the transcript levels of additional control genes were analyzed. Transcript levels of various constitutively expressed genes were similar in Wh, LB and DB cells, supporting the conclusion that C. glabrata HLP is selectively regulated by switching.
- the level of HLP transcript in the three switch phenotypes of C. glabrata was assessed by slot blot analysis. The level of transcript was lowest in Wh cells, intermediate in LB cells and highest in DB cells. Densitometric scans provided relative transcript ratios of 1:20:25 for Wh:LB:DB.
- Example 2 PCR-based strategy using degenerate primers to identify HLP homologues
- Degenerate primers may be designed that are complementary to stretches of DNA encoding highly conserved domains of HLP proteins. Exemplary highly conserved domains include regions 1 and 3 of the C. albicans HLP indicated in FIGURE 2.
- Region 1 CaHLP-N: 5'-ATR GTS RTS TTR GGT GAA ATR ATR CC-3'
- Region 3 CaHLP-Cl: 5'-GGD GTC ATS ATN TCN TNR AC-3'
- PCR reactions may be performed using either total genomic DNA or total RNA pool from Candida hypha cultures.
- the amplifications may be performed using either classical Taq polymerase (Life Technologies).
- the cycle conditions used will be 92°C for 1 min, 36°C for 1 min and 68 °C for 90 sec and 40 cycles.
- high fidelity long PCR protocol will be more reproducible and will result in consistent amplified products ranging in size from 250 bp to 500 bp.
- the pool of PCR products will be cloned into pGEM-T easy vector for sequence analysis.
- the PCR insert library will be screened and sequenced to reveal clones that encode hemolysin-like genes. Once it is confirmed that the insert contains sequences for a putative hemolysin gene, the full-length gene will be cloned using techmques well known in the art. The regulation of the gene by phenotype switching and the function of the gene product can then be determined.
- Example 3 Using non-hemolytic Saccharomyces cerevisiae system to screen for genes for Candida hemolytic activity S. cerevisiae has been used extensively to identify Candida genes either based on functional complementation of homologous genes or functional induction of new activities associated with heterologous non-homologous genes. Boone et al. (1991); Gillum et al. (1984); Rosenbluh et al. (1985); Fu et al. (1998); Gaur et al (1997).
- the main principle of functional complementation is to identify Candida HLP polynucleotides by gain of function analysis of cells transformed by either genomic or cDNA libraries.
- Two research groups have recently demonstrated the power of this experimental strategy.
- ECMs extracellular matrix proteins
- a genomic library of Candida will be constructed in a 2 / x-based S. cerevisiae shuttle vector (PEMBLYe30) with Leu2 as a selectable marker and will be used in the study.
- a 2 ⁇ -based genomic library was chosen rather than a centromere based genomic library because the former system will exhibit greater sensitivity for identifying hemolytic factor due to higher plasmid copy number per cell resulting in production of higher levels of hemolytic activity.
- a Leu2 " S. cerevisiae strain will be transformed with a Candida genomic library using lithium acetate transformation protocol. Schiestl et al. (1989). Following transformation, cells will be spread on selective SD agar plates without leucine. After 4 days of growth at 30 °C, the total number of transformants will be scored. Approximately 10,000 to 25,000 transformants representing 6 to 8 genomic equivalents (considering the average size of DNA inserts to be 5 to 7 Kb) will be included in the hemolytic activity screen. The individual transformants will be picked and collected in 20 to 25 pools, each pool consisting of approximately 1000 clones. From each pool, approximately 1000 individual cells will be spread on blood agar plates containing human blood (Manns et al., 1994).
- the plates will be incubated at 30°C for 3 to 4 days and periodically monitored for hemolytic zones surrounding the colonies.
- transformants containing the parental plasmid pEMBLYe30 will also be monitored for hemolytic activity. Those transformants exhibiting a zone of hemolytic activity will be selected for further analysis.
- the plasmid DNA containing Candida putative genes for hemolytic activity will be isolated from the select S. cerevisiae transformants and transformed into E. coli. Both the integrity of the parental plasmid and the size of insert DNA will be determined by agarose gel electrophoresis.
- the next step will be to confirm that the isolated plasmid DNA does contain the gene for hemolytic activity observed in primary transformants. This will be accomplished by transforming the original S.
- NORTHERN BLOT Northern blot analysis of total RNA will be performed to determine whether the hemolysin gene is regulated at the transcriptional level during the white-opaque transition, the bud-hypha transition and/or by environmental parameters such as temperature, pH and constituents of growth medium. The translational product of hemolysin gene will be analyzed by using specific epitope-tagged hemolysins.
- Known sequences from Candida HLPs may be compared to other known nucleotide sequences on various databases. For example, a search revealed three nucleic acids in Stanford's C. albicans genome database, con4-2646, con4-2740 and con4-2796, which were highly homologues to the HLP of C. glabrata. Identification of sequences on the basis of homology will then be followed by structural and functional characterization using the methods described above.
- C. glabrata isolates may be obtained from any source, such as from blood of infected individuals. Isolates were typed as C. glabrata by sugar assimilation pattern and by hybridization to the C. g/ ⁇ br ⁇ t -specific probes Cg6 and Cgl2 (21). Clones were stored at room temperature on a YPD agar slant (2% glucose, 2% Bacto Peptone, 1 % yeast extract, 2% agar, Difco Laboratories, Detroit, MI) in a capped tube. The switch phenotypes were propagated on YPD agar plates containing ImM CuSO 4 at 25 °C. Each of the phenotypes may also be stored at -80° in glycerol.
- PCR amplification of C. glabrata and C. albicans HLP gene were generated in 100 ⁇ l of a reaction mixture containing 10 mM Buffer B (Fischer Scientific, St. Louis, MO), 1.2 mM MgCl 2 , 100 ⁇ M dNTP, 50 muM dNTP, 50 ⁇ M of the 5' primer and 50 ⁇ M of the 3' primer, and 2.5 units of Taq polymerase (Fischer Scientific).
- Buffer B Fr Fischer Scientific, St. Louis, MO
- 1.2 mM MgCl 2 100 ⁇ M dNTP, 50 muM dNTP, 50 ⁇ M of the 5' primer and 50 ⁇ M of the 3' primer
- Taq polymerase Frischer Scientific
- Conditions for PCR cycling included 40 cycles of denaturation at 92 °C for 1 min, annealing at 40°C for 1.5 min, and extension at 68°C for 1.5 min.
- PCR products were gel-purified and used as template for generating radio
- glabrata HLP PCR product was obtained using primers SLF1-N5' ATGTCATCGCAAAACCTCAAT3' and SLF1-C5' CTGCCTGCTAATTTCACCTTG3 ' .
- the PCR product was cloned in E. coli and sequenced in both directions using an ABI model 373A automatic sequencing system and fluorescent Big dye terminator chemistry (Perkin Elmer/Applied Biosystems Inc. , Fostor city, CA). The alignment of nucleotide sequences and comparison with sequences in the databases were performed with the BLASTX-B ⁇ AUTY analysis program.
- DNA fingerprinting and southern blot analysis DNA fingerprinting and southern blot analysis. DNA fingerprinting was performed as described in Schmid et al. (1990) with complex DNA fingerprinting probes (Lockhart et al. (1997)). In brief, total genomic DNA from each of the C. glabrata switch phenotypes was prepared by the method of Scherer et al. (1987). Approximately 1 ⁇ g of total genomic DNA were digested with EcoRI (4 U/ ⁇ g of DNA) and the resulting fragments electrophoresed at 35 V for 15 hr in a 0.65% (w/v) agarose gel.
- DNA was transferred by capillary blotting to Hybond N + nylon membrane (Amersham Parmacie Biotech, Buckinghamshire, England), hybridized with randomly primed [ 32 P] dCTP-labeled probe, and autoradio graphed as described in Schmid et al. (1990).
- DNA was digested with Sail, the digestion fragments were resolved in a 0.8% (w/v) agarose gel, and the Southern blots were hybridized with randomly primed [ 32 P] dCTP-labeled probes.
- Slot blot and northern analysis of transcripts Total cellular RNA was isolated by methods described in Srikantha et al.
- pellets of 3xl0 8 washed cells from 3 day old colonies were frozen, mixed with an equal volume of acid-washed glass beads (400 ⁇ m diameter) and 450 ⁇ l of RNA extraction buffer from a RNAeasy Mini Kit (Qiagen lnc, Valencia, CA), and agitated with a bead beater device (Biospec Products, BartlesviUe, OK).
- Two ⁇ g of total cell RNA were immobilized on a Zetabind Nylon membrane (CUNO, Inc., Meriden, CT) using the slot blot apparatus PR48 (Hoefer Pharmacia Biotech. Inc., San Francisco, CA), hybridized with randomly primed 32 P-labeled probe, and autoradioraphed.
- Hybridization intensities were compared by scanning the slot blots with the "Densitometry of Lanes" option of the DENDRON software package version 2.0 (ensitometry of Lanes" option of the DENDRON software package version 2.0 (gauch lnc, Iowa City, IA). To perform successive hybridizations of the slot blot with different probes, the previous probe was stripped using standard methods. Northern blot hybridization was performed according to methods described in Kvaal et al. (1997).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001230890A AU2001230890A1 (en) | 2000-01-12 | 2001-01-11 | Candida hemolysin - like proteins |
US10/169,103 US20040029219A1 (en) | 2001-01-11 | 2001-01-11 | Candida hemolysin-like proteins |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17568300P | 2000-01-12 | 2000-01-12 | |
US60/175,683 | 2000-01-12 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2001051517A2 WO2001051517A2 (en) | 2001-07-19 |
WO2001051517A3 WO2001051517A3 (en) | 2001-12-20 |
WO2001051517A9 true WO2001051517A9 (en) | 2002-07-18 |
Family
ID=22641209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/000815 WO2001051517A2 (en) | 2000-01-12 | 2001-01-11 | Candida hemolysin - like proteins and their uses |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2001230890A1 (en) |
WO (1) | WO2001051517A2 (en) |
-
2001
- 2001-01-11 WO PCT/US2001/000815 patent/WO2001051517A2/en active Application Filing
- 2001-01-11 AU AU2001230890A patent/AU2001230890A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2001051517A3 (en) | 2001-12-20 |
AU2001230890A1 (en) | 2001-07-24 |
WO2001051517A2 (en) | 2001-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4651703B2 (en) | Novel surface antigen | |
US5620862A (en) | Methods for diagnosing early Lyme disease | |
La Valle et al. | Generation of a recombinant 65-kilodalton mannoprotein, a major antigen target of cell-mediated immune response to Candida albicans | |
US20110268758A1 (en) | Tuberculosis antigen detection assays and vaccines | |
WO1996025519A1 (en) | Virulence-attenuating genetic deletions | |
US20040091901A1 (en) | Immunogenic Mycoplasma hyopneumoniae polypeptides | |
EP1678199B1 (en) | Methods and compositions for mycoplasma pneumoniae exotoxins | |
JP2002516868A (en) | nrdE | |
JP2002543761A (en) | Tuberculosis antigens and methods of use therefor | |
US20040219585A1 (en) | Nontypeable haemophilus influenzae virulence factors | |
US20040242471A1 (en) | Dormancy induced mycobacterium proteins | |
US20040029219A1 (en) | Candida hemolysin-like proteins | |
JP2003501013A (en) | Lawsonia-derived genes and related SodC polypeptides, peptides and proteins and uses thereof | |
JP2003521881A (en) | Lawsonia-derived genes and related OmpH polypeptides, peptides and proteins and uses thereof | |
WO2001051517A9 (en) | Candida hemolysin - like proteins and their uses | |
WO1994026312A1 (en) | METHODS AND COMPOSITIONS FOR DETECTING AND TREATING MYCOBACTERIAL INFECTIONS USING AN inhA GENE | |
US6270767B1 (en) | Trypanosoma cruzi antigen, gene encoding therefor and methods of detecting and treating chagas disease | |
JPH11146794A (en) | Mray | |
JPH11253171A (en) | Dexb | |
AU2903700A (en) | Vaccine | |
US6433137B1 (en) | TUP1 sequences from Candida albicans and methods for screening agents for inhibiting virulence in Candida albicans using TUP1 | |
JPH11137248A (en) | Mura | |
JP2002522010A (en) | nrdF | |
AU2004278035B2 (en) | Methods and compositions for Mycoplasma pneumoniae exotoxins | |
JPH11253176A (en) | Murf |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1-28, DESCRIPTION, REPLACED BY NEW PAGES 1-26; PAGES 29-31, CLAIMS, REPLACED BY NEW PAGES 27-30; PAGES 1/4-4/4, DRAWINGS, REPLACED BY NEW PAGES 1/5-5/5; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10169103 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |